Cargando…

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

INTRODUCTION: Treatment of recurrent primary pediatric brain tumors remains a major challenge, with most children succumbing to their disease. We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in children and young adults with recurrent and progress...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fangusaro, Jason, Cefalo, Maria Giuseppina, Garré, Maria Luisa, Marshall, Lynley V., Massimino, Maura, Benettaib, Bouchra, Biserna, Noha, Poon, Jennifer, Quan, Jackie, Conlin, Erin, Lewandowski, John, Simcock, Mathew, Jeste, Neelum, Hargrave, Darren R., Doz, François, Warren, Katherine E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218626/ https://www.ncbi.nlm.nih.gov/pubmed/34168987 http://dx.doi.org/10.3389/fonc.2021.660892

Ejemplares similares

4047 EEG as a Predictor of Post-Stroke Recovery: A Systematic Review and Meta-Analysis
por: Vatinno, Amanda, et al.
Publicado: (2020)

Microstructure and Corrosion Resistance of AA4047/AA7075 Transition Zone Formed Using Electron Beam Wire-Feed Additive Manufacturing
por: Filippov, Andrey, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
por: Bjorklund, Chad C., et al.
Publicado: (2019)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Pomalidomide-induced lung injury: A case report
por: Vivien, Alexandre, et al.
Publicado: (2023)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Pomalidomide-induced changes in the pancreatic tumor microenvironment and potential for therapy
por: Storz, Peter
Publicado: (2019)

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
por: Shimizu, Nobuyuki, et al.
Publicado: (2021)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Young, Mary H., et al.
Publicado: (2021)

Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries
por: Brownsey, Duncan K., et al.
Publicado: (2021)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
por: Zhuang, Yan, et al.
Publicado: (2023)

Comparative Quality Control of Titanium Alloy Ti–6Al–4V, 17–4 PH Stainless Steel, and Aluminum Alloy 4047 Either Manufactured or Repaired by Laser Engineered Net Shaping (LENS)
por: Eliaz, Noam, et al.
Publicado: (2020)

Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
por: Terpos, Evangelos, et al.
Publicado: (2013)

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer
por: Amato, Robert J., et al.
Publicado: (2011)

Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB
por: Shirai, Yoshihiro, et al.
Publicado: (2018)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
por: Li, Yan, et al.
Publicado: (2018)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM
por: Park, Hyunkyung, et al.
Publicado: (2022)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023)

Pomalidomide combinations are a safe and effective option after daratumumab failure
por: Brioli, Annamaria, et al.
Publicado: (2023)

Complete chloroplast genomes of the Chlamydomonas reinhardtii nonphotosynthetic mutants CC-1375, CC-373, CC-4199, CC-2359 and CC-1051
por: DeShaw, Alexandra E., et al.
Publicado: (2017)

Absorption, metabolism and excretion of [(14)C]pomalidomide in humans following oral administration
por: Hoffmann, Matthew, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)

Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo
por: Saito, Nobuhiro, et al.
Publicado: (2018)

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
por: Vo, Manh-Cuong, et al.
Publicado: (2018)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Inclusion complexation of the anticancer drug pomalidomide with cyclodextrins: fast dissolution and improved solubility
por: Szabó, Zoltán-István, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjes7pi6ga4jf2bh1m33scu4k3